Head and Neck Neoplasms
Conditions
Keywords
SCB01A, squamous cell carcinoma of head and neck
Brief summary
The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.
Detailed description
From pre-clinical pharmacology and phase I clinical study SCB01A has demonstrated promising anticancer action with a vascular disrupting activity that has the potential for treatment of various malignancies, particularly for patients with drug resistance. The drug has been studied in human subjects in a dose escalation phase I study and has shown to be safe for up to 2 cycles of 24 mg/m2 (each cycle consisting of one intravenous \[i.v.\] administration of SCB01A via a central line every 3 weeks). In the phase I study, partial response (PR) (shrinkage of tumor size to 50%) was observed in cycle 9 (3 mg/m2) of one subject with right buccal squamous cell carcinoma and 19/33 (58%) subjects had stable disease (SD) for more than 2 cycles. Pre clinical study of SCB01A showed that the concentrations at which tubulin inhibition occurred were around 80 nM for 24-hour exposure or 200 nM for 6-hour exposure. However, pharmacokinetic (PK) results of phase I study showed that the average elimination half-life (t1/2) of a 3-hours i.v. infusion of SCB01A is approximately 2.5 hours and almost no SCB01A can be detected after 10 hours, indicating most subjects were treated in short API exposure time and may have been insufficient to achieve efficacy. Therefore, to extend the exposure duration above effective concentration in blood may increase the treatment efficacy. The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.
Interventions
DRUGSCB01A
intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Sponsors
SynCore Biotechnology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged ≥20 years; 2. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment; 3. Histological or cytological confirmed squamous cell carcinoma of head and neck, excluding nasopharyngeal carcinoma; 4. Subjects with unresectable, unfeasible radiotherapy, recurrent or metastatic head and neck squamous cell carcinoma, after previous treatment with platinum agent; 5. Subjects must have at least one measurable tumor lesion as defined by RECIST version 1.1 as assessed by the investigator (local radiological image assessment) or clinically evaluable disease. Physical and neurological examinations, and radiographic studies have to be performed within 28 days of Cycle 1 Day 1; 6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1; 7. Life expectancy of 12 weeks or longer; 8. Concurrent local therapy is not allowed, but concurrent palliative radiation therapy to non-measurable sites of disease such as painful bone metastasis is permitted; 9. All eligible subjects of childbearing potential have to use effective contraception; that is, double barrier contraceptive methods; 10. Documented progressive disease within past 6 months; 11. Adequate bone marrow reserve, cardiac, renal and liver function: 1. Absolute neutrophil count (ANC) \> 1.5 x 109/L; 2. White blood cell (WBC) \> 3 x 109/L; 3. Platelet count \> 75 x 109/L; 4. Hemoglobin \> 9 g/dL ( \> 5.6 mmol/l); 5. Prothrombin time (PT)/international normalized ratio (INR) ≤1.5 x upper limit of normal (ULN); 6. Creatinine clearance (Cockcroft & Gault formula) \>50 mL/min; 7. Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) and Alkaline Phosphatase (ALP) \< 3 x ULN; AST/ALT≦5 x ULN if liver metastasis; 8. Serum albumin ≥ 3 g/dL; 9. Total Bilirubin ≤ 1.5 x ULN; 10. QTc \<450 msec
Exclusion criteria
1. Known primary CNS malignancy or CNS involvement (except for brain metastases that have been treated and are stable and subject is off steroids); 2. Chemotherapy, radiation therapy, major surgery or investigational agents including immune or target therapies less than 4 weeks prior to study drug treatment; 3. History of malignancy other than head and neck cancer with the exception of early stage non-melanoma skin cancer or carcinoma in situ of cervix; 4. History of liver cirrhosis; 5. Active hepatitis B or hepatitis C infection; 6. Clinical significant pulmonary obstructive or clinical significant pulmonary restrictive diseases (grade \>2); 7. Clinically significant cardiac disease (NYHA class \> 2); 8. Other serious illness or medial conditions, such as active infection, unresolved bowel obstruction, or psychiatric disorders; 9. Known HIV positivity; 10. Pregnant or breast-feeding subjects, and men and women of child-bearing potential not using effective contraception while on study treatment; 11. Known hypersensitivity to any component of SCB01A or excipients including Solutol®, alcohol, and PEG300; 12. History of exposure to SCB01A or its analogues; 13. History of active or significant neurological disorder or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere with the clinical and radiological evaluation of central nervous system during the trial; 14. Peripheral neuropathy (≥ grade 2); 15. Any other reason the investigator deems the subject to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) During Treatment Phase | Up to approximately 15 months (assessed continuously during treatment) | Objective response rate (ORR) was defined as complete response (CR) + partial response (PR), according to RECIST v1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From the start of treatment up to either first observation of progressive disease or occurrence of death, up to approximately 15 months (assessed continuously during treatment) | PFS is defined as the time from the start of treatment up to the date of first progression based on RECIST v1.1 or the date of death, which ever comes first. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
| Overall Survival (OS) | From the start of treatment up to death from any cause or last day known to be alive, up to approximately 15 months (assessed continuously during treatment) | OS is defined as the as the time from the start of treatment up to the time that the subject is still alive. |
| Best Overall Tumor Response | Up to approximately 15 months (assessed continuously during treatment) | Best overall tumor response is defined as an objective response or stable disease of treatment phase. |
Countries
Taiwan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SCB01A Alone intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
SCB01A: intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. | 10 |
| Total | 10 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 2 |
| Overall Study | Lack of Efficacy | 4 |
| Overall Study | Physician Decision | 4 |
Baseline characteristics
| Characteristic | SCB01A Alone |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants |
| ECOG at Screening visit 0 | 4 Participants |
| ECOG at Screening visit 1 | 6 Participants |
| Race/Ethnicity, Customized Asian | 10 participants |
| Region of Enrollment Taiwan | 10 participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 3 | 2 / 4 | 0 / 3 |
| other Total, other adverse events | 2 / 3 | 4 / 4 | 2 / 3 |
| serious Total, serious adverse events | 2 / 3 | 2 / 4 | 0 / 3 |
Outcome results
Primary
Objective Response Rate (ORR) During Treatment Phase
Objective response rate (ORR) was defined as complete response (CR) + partial response (PR), according to RECIST v1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 15 months (assessed continuously during treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SCB01A Alone | Objective Response Rate (ORR) During Treatment Phase | 0 Participants |
Secondary
Best Overall Tumor Response
Best overall tumor response is defined as an objective response or stable disease of treatment phase.
Time frame: Up to approximately 15 months (assessed continuously during treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SCB01A Alone | Best Overall Tumor Response | 3 Participants |
Secondary
Overall Survival (OS)
OS is defined as the as the time from the start of treatment up to the time that the subject is still alive.
Time frame: From the start of treatment up to death from any cause or last day known to be alive, up to approximately 15 months (assessed continuously during treatment)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SCB01A Alone | Overall Survival (OS) | 292 days |
Secondary
Progression Free Survival (PFS)
PFS is defined as the time from the start of treatment up to the date of first progression based on RECIST v1.1 or the date of death, which ever comes first. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: From the start of treatment up to either first observation of progressive disease or occurrence of death, up to approximately 15 months (assessed continuously during treatment)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SCB01A Alone | Progression Free Survival (PFS) | 125 days |